traditionally painful and invasive biopsies. Their company is developing a proprietary product that will not only allow researchers to identify and capture rare and difficult to harvest cancer cells in a microfluidic chip but also enable them to conduct downstream molecular analysis. This technology allows for the development of personalized therapies as well as the ability to monitor patient prognosis.